Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765674 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,191
- Enrollment target
NCT00765674 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,191 participants.
The verdict
NCT00765674, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,191 participants
- Enrollment target
Study Summary
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Interventions
- DRUG Placebo
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,191 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765674
The ClinicalTrials.gov registry entry for NCT00765674 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00765674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765674 about?
NCT00765674 is a clinical study titled "Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension". This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
What is the current status of trial NCT00765674?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,191 participants. The study started on 2008-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00765674?
The interventions under investigation include: Placebo (DRUG), Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00765674?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.